Skip to content
HowShorted

Tyra Biosciences, Inc. short interest in 2023

In 2023, Tyra Biosciences, Inc.'s disclosed short interest ran from 2.89% of shares outstanding on 13 Jan 2023 to 3.35% on 29 Dec 2023, a change of +0.46 percentage points. The year's high was 4.32% on 15 Sep 2023 and its low 2.86% on 28 Feb 2023, averaging 3.57% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 93.43 days on 15 May 2023. Full history: Tyra Biosciences, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Tyra Biosciences, Inc. in 2023

2023 in figures

Start of year
2.89% (13 Jan 2023)
End of year
3.35% (29 Dec 2023)
Change
+0.46 pp
High
4.32% (15 Sep 2023)
Low
2.86% (28 Feb 2023)
Average
3.57%
Highest days to cover
93.43 (15 May 2023)
SEC filings marked
8

Every report in 2023

Tyra Biosciences, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20232.89%66.65
31 Jan 20232.88%87.25
15 Feb 20232.87%9.16
28 Feb 20232.86%29.88
15 Mar 20233.05%21.82
31 Mar 20233.25%25.8610-K filed, results (8-K)
14 Apr 20233.38%73.78
28 Apr 20233.40%70.73
15 May 20233.37%93.4310-Q filed, results (8-K)
31 May 20233.47%45.22
15 Jun 20233.42%24.42
30 Jun 20233.71%6.74
14 Jul 20233.76%22.14
31 Jul 20233.97%34.20
15 Aug 20234.15%46.1310-Q filed, results (8-K)
31 Aug 20234.18%44.25
15 Sep 20234.32%41.79
29 Sep 20234.14%35.97
13 Oct 20233.87%19.28
31 Oct 20234.13%20.60
15 Nov 20233.86%33.8210-Q filed, results (8-K)
30 Nov 20233.87%35.19
15 Dec 20233.61%21.60
29 Dec 20233.35%9.63

See also: Tyra Biosciences, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.